Form 4: Corcept Therapeutics Executive Exercises Options and Sells Shares Under Pre-Arranged Plan

Sean Maduck, President of Corcept Endocrinology, exercised stock options and subsequently sold a portion of his common stock holdings in Corcept Therapeutics on July 1, 2025, as part of a pre-arranged 10b5-1 trading plan.

Summary

• Sean Maduck, President of Corcept Endocrinology at Corcept Therapeutics Inc. (CORT), executed transactions involving the company's common stock on July 1, 2025.
• He exercised stock options to acquire 205 shares of common stock at an exercise price of $5.05 per share.
• Concurrently, he sold 205 shares of common stock at a weighted average price of $73.4523 per share, with individual sale prices ranging from $73.40 to $73.62.
• These transactions were conducted pursuant to a Rule 10b5-1 trading plan that was adopted by Mr. Maduck on September 5, 2024.
• Following these transactions, Mr. Maduck directly holds 17,705 shares of common stock, which includes 1,877 shares underlying unvested restricted stock awards granted between September 2024 and June 2025, vesting on the one-year anniversary of their respective grant dates.
• He also indirectly holds 89,693 shares through the Sean and Molly Maduck Living Trust and 10,000 shares through Duckhill Capital, LLC.
• Additionally, Mr. Maduck directly holds 61,781 unexercised stock options with an exercise price of $5.05, which are fully exercisable and expire on May 2, 2026.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive. While an insider sale can sometimes be viewed negatively, the fact that it was executed under a pre-arranged 10b5-1 plan mitigates concerns about reactive selling. The significant difference between the exercise price and sale price also indicates a profitable transaction for the insider.

Positives

• The sale price of $73.4523 per share is significantly higher than the exercise price of $5.05, indicating a substantial profit for the reporting person on the exercised options.
• The transaction was executed under a pre-arranged 10b5-1 trading plan, which suggests a planned and systematic approach to managing equity holdings rather than a reactive sale.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived negatively by investors as it reduces the insider's direct equity stake in the company.

Risks

• No specific company risks are mentioned in this Form 4 filing. However, insider selling, even under a 10b5-1 plan, can sometimes be interpreted by the market as a signal that the stock price may be nearing a peak or that the insider perceives less upside, which could potentially lead to negative investor sentiment.

Future Outlook

No forward-looking statements or guidance are provided in this Form 4 filing, as it primarily reports past insider transactions.

Industry Context

This Form 4 filing reports an individual insider transaction and does not provide broader industry context or trends.

Management Changes

Related Party Transactions

• Sean Maduck indirectly holds 89,693 shares through the Sean and Molly Maduck Living Trust, of which he is a co-trustee.
• Sean Maduck indirectly holds 10,000 shares through Duckhill Capital, LLC, of which he is President, though he disclaims beneficial ownership except to the extent of his pecuniary interest.

Stakeholder Impact

• Shareholders: The sale of shares by a key executive, even under a 10b5-1 plan, could be interpreted by some shareholders as a signal, potentially influencing sentiment. However, the small number of shares sold relative to total holdings and the pre-planned nature mitigate significant negative impact.
• Employees: No direct impact on employees is indicated by this transaction.
• Customers: No direct impact on customers is indicated by this transaction.
• Suppliers: No direct impact on suppliers is indicated by this transaction.
• Creditors: No direct impact on creditors is indicated by this transaction.

Key Dates

Keywords

Corcept Therapeutics, CORT, Form 4, insider trading, stock option exercise, stock sale, 10b5-1 plan, Sean Maduck, executive compensation, corporate governance